Develops predictive tests for pregnancy complications, aiming to improve maternal and fetal health outcomes.
Sera Prognostics, Inc. is a leading diagnostic company focused on enhancing women's health through the discovery, development, and commercialization of biomarker tests. The company specializes in improving pregnancy outcomes with a particular emphasis on its flagship product, the PreTRM test. This innovative blood-based biomarker test accurately predicts the risk of spontaneous preterm birth in asymptomatic singleton pregnancies, providing crucial insights for healthcare providers and expecting mothers.
In addition to the PreTRM test, Sera Prognostics is advancing a robust portfolio of product candidates targeting various pregnancy-related conditions. These include initiatives aimed at addressing critical maternal health issues such as preeclampsia, molecular time-to-birth assessments, gestational diabetes mellitus, fetal growth restriction, stillbirth prevention, and postpartum depression. Through these advancements, the company aims to revolutionize prenatal care and improve outcomes for mothers and babies.
Founded in 2008 and headquartered in Salt Lake City, Utah, Sera Prognostics continues to lead the forefront of women's health diagnostics. With a steadfast commitment to research and innovation, the company is dedicated to advancing the field of prenatal testing, empowering healthcare providers with the tools needed to make informed decisions and ultimately improving maternal and fetal health worldwide.